Imunon (IMNN) Competitors $5.48 -0.10 (-1.79%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. RLMD, NRXP, QNTM, INMB, BRNS, ATNM, FGEN, TPST, VRCA, and LTRNShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Relmada Therapeutics (RLMD), NRx Pharmaceuticals (NRXP), Quantum Biopharma (QNTM), INmune Bio (INMB), Barinthus Biotherapeutics (BRNS), Actinium Pharmaceuticals (ATNM), FibroGen (FGEN), Tempest Therapeutics (TPST), Verrica Pharmaceuticals (VRCA), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Its Competitors Relmada Therapeutics NRx Pharmaceuticals Quantum Biopharma INmune Bio Barinthus Biotherapeutics Actinium Pharmaceuticals FibroGen Tempest Therapeutics Verrica Pharmaceuticals Lantern Pharma Relmada Therapeutics (NASDAQ:RLMD) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Does the media prefer RLMD or IMNN? In the previous week, Relmada Therapeutics had 4 more articles in the media than Imunon. MarketBeat recorded 6 mentions for Relmada Therapeutics and 2 mentions for Imunon. Imunon's average media sentiment score of 1.45 beat Relmada Therapeutics' score of 0.98 indicating that Imunon is being referred to more favorably in the news media. Company Overall Sentiment Relmada Therapeutics Positive Imunon Positive Do insiders and institutionals believe in RLMD or IMNN? 45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 20.7% of Relmada Therapeutics shares are owned by insiders. Comparatively, 6.0% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate RLMD or IMNN? Relmada Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 223.62%. Imunon has a consensus target price of $232.50, indicating a potential upside of 4,166.06%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than Relmada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has better earnings & valuation, RLMD or IMNN? Imunon has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$79.98M-$2.22-0.70Imunon$500K26.60-$18.62M-$12.95-0.42 Which has more risk & volatility, RLMD or IMNN? Relmada Therapeutics has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Imunon has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Is RLMD or IMNN more profitable? Relmada Therapeutics' return on equity of -223.17% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -223.17% -180.41% Imunon N/A -405.07%-158.41% SummaryImunon beats Relmada Therapeutics on 9 of the 14 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.30M$3.11B$5.72B$10.26BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.4221.2575.1026.36Price / Sales26.60390.88498.56167.32Price / CashN/A44.4425.8129.90Price / Book1.439.6513.236.29Net Income-$18.62M-$53.18M$3.28B$270.30M7 Day Performance-6.36%0.47%0.32%1.95%1 Month Performance-14.84%4.68%4.73%6.14%1 Year Performance-66.36%10.19%73.16%27.92% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.6473 of 5 stars$5.48-1.8%$232.50+4,142.7%-64.2%$13.37M$500K-0.4230Positive NewsShort Interest ↓RLMDRelmada Therapeutics4.1295 of 5 stars$1.60-3.0%$5.00+212.5%-46.0%$54.77MN/A-0.7210News CoverageNRXPNRx Pharmaceuticals3.3237 of 5 stars$2.84+3.3%$34.50+1,114.8%+74.4%$54.48MN/A-1.272Positive NewsQNTMQuantum Biopharma0.4903 of 5 stars$13.00-7.5%N/A+345.0%$53.63MN/A-0.93N/AINMBINmune Bio3.4905 of 5 stars$1.81-7.2%$18.40+916.6%-63.9%$51.84M$10K-0.7310News CoveragePositive NewsShort Interest ↓BRNSBarinthus Biotherapeutics2.7574 of 5 stars$1.22-2.0%$3.00+146.9%-17.3%$50.49M$14.97M-0.70107Positive NewsATNMActinium Pharmaceuticals2.223 of 5 stars$1.60+1.3%$4.50+181.3%-12.9%$49.91MN/A-1.1530FGENFibroGen4.4607 of 5 stars$11.16-7.8%$43.00+285.3%+0.8%$48.93M$29.62M-29.37570News CoverageAnalyst UpgradeGap DownTPSTTempest Therapeutics2.4789 of 5 stars$10.85-1.3%$30.00+176.5%-47.4%$48.80MN/A-0.7420VRCAVerrica Pharmaceuticals4.0741 of 5 stars$5.06-1.0%$80.00+1,481.0%-74.9%$48.22M$7.57M-0.6140Positive NewsLTRNLantern Pharma2.3727 of 5 stars$4.06-5.8%$25.00+515.8%-5.2%$46.54MN/A-2.2820News CoverageGap UpTrading Halted Related Companies and Tools Related Companies RLMD Competitors NRXP Competitors QNTM Competitors INMB Competitors BRNS Competitors ATNM Competitors FGEN Competitors TPST Competitors VRCA Competitors LTRN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNN Stock Alerts